# KLOW Side Effects and Safety Signals — KLOW peptide Audit > KLOW Side Effects and Safety Signals: WADA-prohibited TB-500, no blend safety data, an inherent PK mismatch, and the cited component-level cautions for the KLOW peptide blend. An inspection ledger of the four-peptide blend's status: not FDA-approved, one arm banned in sport, zero combination safety data, and a built-in pharmacokinetic mismatch. ## The short version The honest answer on KLOW side effects and safety signals starts with a blank: there is no safety dataset for the four-peptide blend, because the blend was never tested. So we work from the parts and the regulatory record. One hard fact first — TB-500 is a fragment of thymosin beta-4, which is banned at all times under the world anti-doping rules, so any athlete using KLOW is breaking those rules. None of the four parts is FDA-approved. The parts clear the body at very different speeds, so a single shot can't keep all four working together. From there the cautions are mostly theoretical — reasoned from how the parts work, not from a study of the blend: a copper load from GHK-Cu, an angiogenesis (new-blood-vessel) concern for anyone with cancer, and an immune-dampening concern from the KPV arm. We cite each one and label which are theoretical. ## Regulatory status: not approved, and one arm is banned in sport None of the four peptides — individually or as KLOW — is FDA-approved for human use; the blend is a research-only co-formulation. GHK-Cu appears in cosmetics, and BPC-157 was placed by the FDA in category 2 of the 503A bulk-substances review. The sharpest status fact is the doping one: TB-500 is the synthetic fragment of thymosin beta-4, and thymosin beta-4 sits on the WADA Prohibited List under S2 (peptide hormones, growth factors), prohibited at all times in and out of competition [11]. A 2026 Sports Medicine review of approved and unapproved musculoskeletal peptides lists both TB-500 and BPC-157, concluding that such compounds show animal-model promise but scarce human safety data, potential for serious harm, and operation largely outside regulatory oversight [12]. Because TB-500 is one of the four arms, the blend inherits that status outright. ## The structural problem: no blend data and a pharmacokinetic mismatch The deepest safety signal is not a side effect — it is an absence. No controlled study has tested the four-peptide blend against monotherapy, any subset, or placebo, so there is no safety profile for KLOW as administered. Layered on top is a pharmacokinetic mismatch built into the chemistry: BPC-157's formal PK/ADME study reports a very short elimination half-life — under 30 minutes — with modest intramuscular bioavailability and rapid breakdown into amino-acid fragments [7], and the two tripeptides KPV and GHK-Cu clear even faster, while the TB-500 fragment behaves differently from native thymosin beta-4. A single co-formulated vial therefore cannot hold all four constituents at matched exposures over time [12]. There is also an unstudied copper-redox compatibility question from co-dissolving GHK-Cu's copper(II) with three other peptides. These are mechanistic and structural cautions, not documented clinical events. ## Component-level cautions: cancer, copper, and the immune arm Three theoretical, cited cautions follow from how the components work. First, angiogenesis: three of the four arms — BPC-157, TB-500/thymosin beta-4 and GHK-Cu — promote new blood-vessel growth, with BPC-157 acting through the VEGFR2-Akt-eNOS pathway [6], and thymosin beta-4 increasing angiogenesis in wound models [1]. Because solid tumors depend on new vessels, accelerating angiogenesis is a theoretical concern for anyone with an active or recent cancer; no study has tested it either way. Second, copper: GHK-Cu is the mass-dominant component (about 50 of 80 mg), each molecule carrying a chelated copper(II) ion, and a human skin study quantified real copper delivery and dermal-depot formation from it [13]. For anyone with a copper-handling disorder such as Wilson's disease, repeated copper delivery is a theoretical concern. Third, the immune arm: KPV suppresses NF-kappaB-driven inflammatory transcription and is taken up preferentially into immune cells via PepT1 [3][14], so dampening inflammation is a theoretical variable during active infection or autoimmune disease. Community-reported side effects — injection-site reactions, transient fatigue, headache, flushing, mild GI upset — are catalogued, labeled anecdotal, on the [reported effects and cautions](/effects) page. --- A claim-by-claim teardown of the four-peptide KLOW literature — each constituent inspected against its own studies and tagged for what the evidence actually carries, with the combination left as the honest blank no controlled trial has filled; no clinic operates this rig and nothing here is dispensed or sold.